Vivek Subbiah: SCRI Phase 1 Denver DDU is celebrating its 10th anniversary

Razelle Kurzrock shared a post by Vivek Subbiah on X:

“I know some of those faces.

The offspring of our phase I department at MD Anderson Changing cancer across the country.”

Quoting Vivek Subbiah’s post:

“Excited to visit our Sarah Cannon Docs.

Denver Drug Development Unit and meet with our amazing Phase 1 doctors Drs. Gerald Falchook and Jason Timothy Henry!

Our SCRI Phase 1 Denver DDU is celebrating its 10th anniversary this year and has emerged as one of Colorado’s premier oncology clinical trial units, bringing cutting-edge clinical trials to patients in the Denver area.

So thankful to all the patients and their caregivers volunteering for novel phase 1 trials, physician leaders, fantastic clinical trial staff, local Denver community, collaborators and everyone making this unit a huge success. ”

Razelle Kurzrock, MD, is a world-renowned physician-scientist leader in precision medicine as well as in the development of novel therapeutics in the field of oncology. She is recognized for founding, developing and chairing one of the largest Phase 1 clinical trial departments globally while at the University of Texas MD Anderson Cancer Center; the central theme of the department was a personalized medicine strategy. She is also one of the pioneering trialists of the WINTHER precision medicine international trial focusing, for the first time, on transcriptomics in addition to genomics. This trial was the signature study of the Worldwide Innovative Network (WIN) consortium (Nature Medicine). She also developed and led some of the first tumor-agnostic cancer clinical trials.

During her time at the University of California San Diego Health, Dr. Kurzrock’s charge was founding and leading the Center for Personalized Cancer Therapy as well as the Experimental Therapeutics program, and she also founded a Rare Tumor Clinic focused on precision medicine. The signature study of the center was the I-PREDICT study (Nature Medicine, 2019) that gave, for the first time, individualized N-of-1 matched combination therapies to patients with lethal malignancies, hence resulting in improved outcomes, and transforming the entire paradigm for oncology treatment. This work was presented at the Nobel Symposium, Karolinska Institute, Stockholm, Sweden in September 2023.

Dr Kurzrock has performed key early-phase studies of 8 drugs that have gone on to FDA approval. Many of her studies have also been incorporated into NCCN guidelines.

Dr. Kurzrock is also an entrepreneur. She is co-founder of CureMatch, and on the Board of CureMetrix, CureMatch, and Xcures.

Dr. Kurzrock is the author of >1000 peer-reviewed articles on PubMed and has a highly exceptional Hirsch index (h-index) score of 147, with over almost 100,000 citations. She has been selected each year since 2019 as one of the world’s most cited scientists worldwide.

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer. He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.